KYNB - FIBROGEN INC

6.84
-0.045   -0.658%

Share volume: 54,751
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$6.88
-0.04
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 0%
Dept financing 41%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-12.64%
3 Months
-18.18%
6 Months
-38.71%
1 Year
1,695.28%
2 Year
280.00%
Key data
Stock price
$6.84
P/E Ratio 
0.23
DAY RANGE
$6.67 - $7.03
EPS 
$47.96
52 WEEK RANGE
$0.23 - $12.60
52 WEEK CHANGE
$1,695.28
MARKET CAP 
49.538 M
YIELD 
N/A
SHARES OUTSTANDING 
4.045 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
0.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$40,077
AVERAGE 30 VOLUME 
$40,492
Company detail
CEO: Enrique A. Conterno
Region: US
Website: fibrogen.com
Employees: 570
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.

Recent news